AR042667A1 - Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico - Google Patents
Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclicoInfo
- Publication number
- AR042667A1 AR042667A1 ARP030104818A ARP030104818A AR042667A1 AR 042667 A1 AR042667 A1 AR 042667A1 AR P030104818 A ARP030104818 A AR P030104818A AR P030104818 A ARP030104818 A AR P030104818A AR 042667 A1 AR042667 A1 AR 042667A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- cycloalkyl
- hydroxy
- aryl
- Prior art date
Links
- -1 AMINO GROUP Chemical group 0.000 title abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 41
- 229910052739 hydrogen Inorganic materials 0.000 abstract 19
- 239000001257 hydrogen Substances 0.000 abstract 19
- 150000002431 hydrogen Chemical group 0.000 abstract 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 12
- 125000003118 aryl group Chemical group 0.000 abstract 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000003277 amino group Chemical group 0.000 abstract 3
- 125000004122 cyclic group Chemical group 0.000 abstract 3
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 206010008118 cerebral infarction Diseases 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010015037 epilepsy Diseases 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical group C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 abstract 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical group C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010048962 Brain oedema Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 1
- 208000006752 brain edema Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002769 corticotropin releasing factor antagonist Substances 0.000 abstract 1
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 abstract 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 1
- 125000005191 hydroxyalkylamino group Chemical group 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000018556 stomach disease Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Abstract
Un objeto de la presente consiste en proporcionar un antagonista de los receptores de CRF que sea efectivo como agente terapéutico o profiláctico para enfermedades en las que se considera que participa CRF, tales como depresión, ansiedad, enfermedad de Alzheimer, mal de Parkinson, corea de Huntington, trastornos alimentarios, hipertensión, enfermedades gástricas, drogadependencia, epilepsia, infarto cerebral, isquemia cerebral, edema cerebral, lesión cefálica externa, inflamación, enfermedades relacionadas con la inmunidad, alopecia, síndrome de intestino irritable, trastornos del sueno, epilepsia, dermatitis, esquizofrenia, etc.. Reivindicación 1: Un derivado de pirrolopirimidina o pirrolopiridina sustituido con un grupo amino cíclico representado por la siguiente fórmula (1), (en donde el grupo amino cíclico está representado por la fórmula (1), en donde el grupo amino cíclico es un amina cíclica saturada de 3 a 8 miembros o una amina cíclica saturada de 3 a 8 miembros en puente con un alquileno C1-5 o alquileno(C1-4)-O-alquileno(C1-4) entre dos átomos de carbono diferentes de la amina cíclica, cuya amina cíclica está sustituida con un grupo representado por -(CR1R2)m-(CH3)n-X, R4 y R5 de modo independiente en átomos de carbono iguales o diferentes de la amina cíclica; X es ciano, hidroxi u -OR9; Y es N o CR10; R1 es hidrógeno, hidroxi, alquilo C1-5, alcoxi(C1-5)-alquilo(C1-5) o hidroxi-alquilo (C1-5); R2 es hidrógeno o alquilo C1-5; R3 es hidrógeno, ciano, alquilo C1-5, alcoxi(C1-5)-alquilo(C1-5) o hidroxi-alquilo (C1-5); m es un número entero seleccionado de 0, 1, 2, 3, 4 y 5; n es 0 ó 1; con la condición de que, cuando X es hidroxi u OR9, y n es 0, m sea un número entero seleccionado de 1, 2, 3, 4 y 5; R4 es hidrógeno, hidroxi, hidroxi-alquilo (C1-5), ciano, ciano-alquilo (C15) o alquilo C1-5; R5 es hidrógeno o alquilo C1-5; R6 es hidrógeno, alquilo C1-5, cicloalquilo C3-8, cicloalquil(C3-8)-alquilo(C1-5), hidroxi, alcoxi C1-5, cicloalcoxi C3-8 o -N(R11)R12; R7 y R8 son iguales o diferentes y son, de modo independiente, hidrógeno, halógeno, alquilo C1-5, cicloalquilo C3-8, cicloalquil(C3-8)-alquilo(C1-5), hidroxi, alcoxi C1-5, cicloalquiloxi C3-8, -N(R11a)R12a, -CO2R13, ciano, nitro, alquiltio C1-5, trifluorometilo o trifluorometoxi; o R7 y R8 se toman juntos para formar -CH2-CH2-CH2-CH2- o -CH=CH-CH=CH-; R9 es acilo C1-24, alcoxicarbonilo C1-10, aril-alquiloxicarbonilo (C1-5), -CO-O-CHR14-O-CO-R15, -P(=O)(OR14a)OR15a, -CO-(CH2)p-(CHR16)qNR17R18, arilcarbonilo o heteroarilcarbonilo, en donde cada uno de dichos acilo, arilo y heteroarilo está insustituido o sustituido con alcoxi C1-5 y el acilo C1-24 incluye opcionalmente de uno a seis enlaces dobles; R10 es hidrógeno, alquilo C1-5, halógeno, ciano o -CO2R19; Ar es arilo o heteroarilo, cuyo arilo o heteroarilo está insustituido o sustituido con 1 o más sustituyentes que son iguales o diferentes, seleccionados del grupo integrado por halógeno, alquilo C1-5, cicloalquilo C3-8, alquenilo C2-5, alquinilo C2-5, alcoxi C1-5, alquiltio C1-5, alquilsulfinilo C1-5, alquilsulfonilo C1-5, ciano, nitro, hidroxi, -CO2R19a, -C(=O)R19a, -CONR11bR12b, -OC(=O)R19a, -NR11bCO2R19a, -S(O)rNR11bR12b, hidroxi-alquilamino(C2-5)-alcoxi(C2-5), trifluorometilo, trifluorometoxi, difluorometoxi, fluorometoxi, metilendioxi, etilendioxi t -N(R20)R21; con la condición de que, cuando X es hidroxi, Y es N y el grupo amino cíclico es un anillo de 5 miembros, entonces Ar sea arilo o heteroarilo, cuyo arilo o heteroarilo está sustituido con al menos uno de los sustituyentes que están seleccionados de halógeno y trifluorometilo; R11 y R12 son iguales o diferentes y son, de modo independiente, hidrógeno, alquilo C1-5, cicloalquilo C3-8 o cicloalquil(C3-8)-alquilo(C1-5); R11a y R12a son iguales o diferentes y son, de modo independiente, hidrógeno, alquilo C1-5, cicloalquilo C3-8, o cicloalquil(C3-8)-alquilo(C1-5); R11b y R12b son iguales o diferentes y son, de modo independiente, hidrógeno, alquilo C1-5, cicloalquilo C3-8 o cicloalquil(C3-8)-alquilo(C1-5); R13 es hidrógeno, alquilo C1-5, cicloalquilo C3-8, cicloalquil(C3-8)-alquilo(C1-5), alcoxi(C1-5)-alquilo(C1-5), cicloalquiloxi(C3-8)-alquilo(C1-5) o fenilo; R14 y R15 son iguales o diferentes y son, de modo independiente, hidrógeno, alquilo C1-5 o aril-alquilo (C1-5); R14a y R15a son iguales o diferentes y son, de modo independiente, hidrógeno, alquilo C1-5 o aril-alquilo (C1-5); R16 es hidrógeno, alquilo C1-5, arilo, heteroarilo, aril-alquilo (C1-5), heteroaril-alquilo (C1-5), hidroxi-alquilo (C1-5), hidroxicarbonil-alquilo (C1-5), hidroxifenil-alquilo (C1-5), alcoxi(C1-5)-alquilo(C1-5), amino-alquilo (C1-5), guanidino-alquilo (C1-5), mercapto-alquilo(C1-5), alquiltio(C1-5)-alquilo(C1-5) o aminocarbonil-alquilo (C1-5); R17 y R18 son iguales o diferentes y son, de modo independiente, hidrógeno, alquilo C1-5, cicloalquilo C3-8, cicloalquil(C3-8)-alquilo(C1-5), acilo C1-10, alcoxicarbonilo C1-10 o aril-alquiloxicarbonilo C1-5; o R16 y R17 se toman juntos para formar -CH2-, -CH2CH2-, -CH2CH2CH2- o -CH2CH2CH2CH2-; p es un número entero seleccionado de 0, 1, 2, 3, 4 y 5; q s 0 ó 1; R19 es hidrógeno o alquilo C1-5; R19a es hidrógeno o alquilo C1-5; r es 1 o 2; R20 y R21 son iguales o diferentes y son, de modo independiente, hidrógeno o alquilo C1-5), sus isómeros individuales, mezclas isoméricas racémicas o no racémicas o sus N-óxidos, o sus sales e hidratos farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002383667 | 2002-12-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042667A1 true AR042667A1 (es) | 2005-06-29 |
Family
ID=32677471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104818A AR042667A1 (es) | 2002-12-26 | 2003-12-23 | Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20050209253A1 (es) |
| EP (2) | EP1467997B8 (es) |
| JP (1) | JP4181126B2 (es) |
| KR (2) | KR100808756B1 (es) |
| CN (1) | CN1692115A (es) |
| AR (1) | AR042667A1 (es) |
| AT (2) | ATE390426T1 (es) |
| AU (1) | AU2003292550B8 (es) |
| BR (1) | BR0307587A (es) |
| CA (1) | CA2485556C (es) |
| CL (1) | CL2003002762A1 (es) |
| DE (2) | DE60319951T2 (es) |
| EA (1) | EA200401060A1 (es) |
| ES (2) | ES2325596T3 (es) |
| HR (1) | HRP20040724A2 (es) |
| MX (1) | MXPA04008081A (es) |
| MY (1) | MY141200A (es) |
| NO (1) | NO20043508L (es) |
| PL (1) | PL371810A1 (es) |
| TW (1) | TWI270549B (es) |
| UA (1) | UA77265C2 (es) |
| WO (1) | WO2004058767A1 (es) |
| ZA (1) | ZA200405982B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1701961A1 (en) * | 2004-01-06 | 2006-09-20 | Taisho Pharmaceutical Co., Ltd | Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group |
| RU2367663C2 (ru) * | 2004-01-06 | 2009-09-20 | Тайсо Фармасьютикал Ко., Лтд. | Производные пирролопиримидина и пирролотриазина |
| CN1910187A (zh) | 2004-01-06 | 2007-02-07 | 大正制药株式会社 | 三氮杂－环戊烷并[cd]茚衍生物 |
| JP2007526906A (ja) * | 2004-03-05 | 2007-09-20 | 大正製薬株式会社 | ピロロピリミジン誘導体 |
| EP1781652A1 (en) * | 2004-06-25 | 2007-05-09 | Taisho Pharmaceutical Co., Ltd | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as crf antagonists |
| JP2007161585A (ja) * | 2004-06-25 | 2007-06-28 | Taisho Pharmaceut Co Ltd | 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体 |
| DE102004042607A1 (de) * | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
| DE102006042143A1 (de) * | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
| DE102006056739A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
| DE102006056740A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| DE102007035367A1 (de) * | 2007-07-27 | 2009-01-29 | Bayer Healthcare Ag | Substituierte Aryloxazole und ihre Verwendung |
| DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
| DE102007061763A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
| DE102007061764A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
| DE102008013587A1 (de) * | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| CA2726020C (en) * | 2008-05-29 | 2016-08-16 | Bayer Schering Pharma Aktiengesellschaft | 2-alkoxy-substituted dicyanopyridines and use thereof |
| WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
| DE102009006602A1 (de) * | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
| DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
| US20120058983A1 (en) | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
| BR112013023266B8 (pt) | 2011-03-15 | 2021-04-06 | L Livermore Nat Security Llc | inibidores da girase tricíclicos |
| EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| AU2014253275B2 (en) | 2013-04-11 | 2018-10-18 | F. Hoffmann-La Roche Ag | BACE1 inhibitors |
| PL2991988T3 (pl) * | 2013-05-02 | 2017-10-31 | Hoffmann La Roche | Pochodne pirolo[2,3-d]pirymidyny jako agoniści receptora cb2 |
| CN114829362A (zh) * | 2019-12-10 | 2022-07-29 | 成都倍特药业股份有限公司 | 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物 |
| CN114646700B (zh) * | 2022-03-01 | 2023-10-20 | 浙江国邦药业有限公司 | 一种（s）-吡咯烷-2-甲腈盐酸盐的检测方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL176526B1 (pl) | 1992-12-17 | 1999-06-30 | Pfizer | Pirolopirymidyny jako związki o działaniu antagonistów czynnika uwalniającego kortykotropinę |
| US5646152A (en) | 1994-06-15 | 1997-07-08 | Pfizer Inc. | Methods of administering CRF antagonists |
| JP2891544B2 (ja) | 1994-06-16 | 1999-05-17 | ファイザー・インコーポレーテッド | ピラゾロおよびピロロピリジン類 |
| WO1998042699A1 (en) | 1997-03-26 | 1998-10-01 | Taisho Pharmaceutical Co., Ltd. | 4-tetrahydropyridylpyrimidine derivatives |
| WO2000053604A1 (en) | 1999-03-11 | 2000-09-14 | Taisho Pharmaceutical Co., Ltd. | Carbamoyl tetrahydropyridine derivatives |
| AR028782A1 (es) * | 2000-07-05 | 2003-05-21 | Taisho Pharmaceutical Co Ltd | Derivados heterociclicos tetrahidropiridino o piperidino |
| CN1910187A (zh) * | 2004-01-06 | 2007-02-07 | 大正制药株式会社 | 三氮杂－环戊烷并[cd]茚衍生物 |
-
2003
- 2003-12-23 TW TW092136594A patent/TWI270549B/zh not_active IP Right Cessation
- 2003-12-23 AR ARP030104818A patent/AR042667A1/es unknown
- 2003-12-24 CN CNA2003801004264A patent/CN1692115A/zh active Pending
- 2003-12-24 US US10/504,981 patent/US20050209253A1/en not_active Abandoned
- 2003-12-24 AU AU2003292550A patent/AU2003292550B8/en not_active Ceased
- 2003-12-24 EP EP03768186A patent/EP1467997B8/en not_active Expired - Lifetime
- 2003-12-24 ES ES06019987T patent/ES2325596T3/es not_active Expired - Lifetime
- 2003-12-24 BR BR0307587-7A patent/BR0307587A/pt not_active IP Right Cessation
- 2003-12-24 CA CA002485556A patent/CA2485556C/en not_active Expired - Fee Related
- 2003-12-24 WO PCT/JP2003/016598 patent/WO2004058767A1/en not_active Ceased
- 2003-12-24 DE DE60319951T patent/DE60319951T2/de not_active Expired - Lifetime
- 2003-12-24 ES ES03768186T patent/ES2302949T3/es not_active Expired - Lifetime
- 2003-12-24 UA UA20040907464A patent/UA77265C2/uk unknown
- 2003-12-24 AT AT03768186T patent/ATE390426T1/de not_active IP Right Cessation
- 2003-12-24 HR HR20040724A patent/HRP20040724A2/hr not_active Application Discontinuation
- 2003-12-24 KR KR1020067025000A patent/KR100808756B1/ko not_active Expired - Fee Related
- 2003-12-24 EP EP06019987A patent/EP1787992B1/en not_active Expired - Lifetime
- 2003-12-24 DE DE60327477T patent/DE60327477D1/de not_active Expired - Lifetime
- 2003-12-24 JP JP2004562918A patent/JP4181126B2/ja not_active Expired - Fee Related
- 2003-12-24 AT AT06019987T patent/ATE430151T1/de not_active IP Right Cessation
- 2003-12-24 MX MXPA04008081A patent/MXPA04008081A/es active IP Right Grant
- 2003-12-24 EA EA200401060A patent/EA200401060A1/ru unknown
- 2003-12-24 KR KR1020047013348A patent/KR100688395B1/ko not_active Expired - Fee Related
- 2003-12-24 PL PL03371810A patent/PL371810A1/xx not_active Application Discontinuation
- 2003-12-24 MY MYPI20034990A patent/MY141200A/en unknown
- 2003-12-26 CL CL200302762A patent/CL2003002762A1/es unknown
-
2004
- 2004-07-27 ZA ZA200405982A patent/ZA200405982B/en unknown
- 2004-08-23 NO NO20043508A patent/NO20043508L/no not_active Application Discontinuation
-
2008
- 2008-04-21 US US12/106,873 patent/US7932259B2/en not_active Expired - Fee Related
-
2010
- 2010-11-22 US US12/951,556 patent/US8455511B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042667A1 (es) | Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico | |
| MX2009003410A (es) | Fosfoindoles enantiomericamente puros como inhibidores de vih. | |
| HRP20220899T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova farmaceutska uporaba | |
| HRP20050688A2 (en) | Pyrimidine derivatives for the prevention of hiv infection | |
| HUP0100950A2 (hu) | Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
| MX2009009422A (es) | Derivados de 3-ciano-piridona 1,4-disustituidos y su uso como moduladores del receptor mglur-2 positivo. | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| TW200718692A (en) | Dihydrobenzofuran derivatives and uses thereof | |
| HRP20120310T1 (hr) | Derivati benzazepina korisni kao antagonisti vazopresina | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
| TW200720266A (en) | Benzodioxane and benzodioxolan derivatives and uses thereof | |
| PE20180796A1 (es) | Macrociclos peptidicos contra acinetobacter baumannii | |
| PA8580301A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| ES2623982T3 (es) | Compuestos heterocíclicos de unión a receptor de quimiocina con eficacia potenciada | |
| UY26872A1 (es) | Derivados de la 4- fenil piridina | |
| EA200901160A1 (ru) | Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она | |
| MX2007004979A (es) | Derivados de indol tetraciclicos como agentes antiviricos. | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| MX2009003874A (es) | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. | |
| MX2010005753A (es) | Derivados de isoxazolo-pirazina. | |
| ATE440834T1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| AR049372A1 (es) | Compuestos biciclicos de amina y composiciones farmaceuticas que los comprenden | |
| AR082633A1 (es) | Analogos de tetraciclina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |